AZN Stock Analysis: Buy, Sell, or Hold?
AZN - AstraZeneca PLC
$181.02
4.59 (2.60%)
▲
5d:
+2.12%
30d:
-4.6%
90d:
-1.66%
HOLD
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Get Alerted When AZN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: AZN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: AZN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$331.27
Based on 10.6% avg growth
INTRINSIC VALUE TODAY
$205.69
12.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: AZN is currently trading at $181.02, which is considered fair relative to its 30-day fair value range of $177.93 to $185.96. From a valuation perspective, the stock is trading at a discount (Forward PE: 22.5) compared to its historical average (27.3). Remarkably, the market is currently pricing in an annual earnings decline of 6.2% over the next few years. This pessimistic expectation contrasts with the company's recent 5.3% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, AZN is in a strong uptrend. The price is approaching resistance at $183.81. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: AZN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $224.49 (+24.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, AZN is in a strong uptrend. The price is approaching resistance at $183.81. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: AZN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $224.49 (+24.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$177.93 -
$185.96
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 24.0% below Wall St target ($224.49)
Trading Range Analysis
30-Day Trading Range
$177.93 -
$185.96
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$173.66
Resistance Level
$183.81
Current Trend
Strong Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
22.51
Wall Street Target
$224.49
(+24.0%)
Revenue Growth (YoY)
12.5%
Earnings Growth (YoY)
5.3%
Profit Margin
17.2%
Valuation Discount vs History
-6.2% cheaper
PE vs Historical
22.5 vs 27.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-6.2%
(market-implied from PE analysis)
1-Year Target
$169.80
(-6%)
2-Year Target
$159.27
(-12%)
3-Year Target
$149.39
(-18%)
3-Yr Target (if PE normalizes)
(PE: 23→27)
$181.21
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.5, Growth: 17.2%)
$291.31
(+61%)
Base:
(SPY PE: 21.8, Growth: 17.2%)
$281.89
(+56%)
Bear:
(PE: 18.5, Growth: 17.2%)
$239.61
(+32%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (27x PE), but valuation improves significantly next year (23x PE) as earnings recover.
Trailing PE: 27.17 | Current EPS (TTM): $6.63
Bull Case
$240.34
(+33%)
Analyst growth 21.3%, PE expands to 29.9
Base Case
$218.49
(+21%)
Market implied 21.3%, PE stable at 27.2
Bear Case
$122.47
(-32%)
Severe decline -20.0%, PE contracts to 23.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 22.5 to 27.3
Stabilization Target:
$219.57
(+21.3%)
PE Expansion Potential:
+21.3%
Share & Embed Analysis
Last updated: June 23, 2026 10:38 PM ET
Data refreshes hourly during market hours. Next update: 11:38 PM
Data refreshes hourly during market hours. Next update: 11:38 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AZN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1219 | 52 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 56 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$254 | 66 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$353 | 64 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$220 | 63 BUY |
